A population-based assessment of specialty physician involvement in cancer clinical trials

Journal of the National Cancer Institute

Volumn 103, Issue 5, 2011, Pages 384-397

  Klabunde, Carrie N ^a   Keating, Nancy L ^c   Potosky, Arnold L ^b,d   Ambs, Anita ^a   He, Yulei ^c   Hornbrook, Mark C ^e   Ganz, Patricia A ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CENTER; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; FEMALE; HEALTH PROGRAM; HUMAN; LUNG CANCER; MALE; MEDICAL SPECIALIST; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; HEALTH CARE SURVEYS; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; PHYSICIAN'S ROLE; PHYSICIAN-PATIENT RELATIONS; PHYSICIANS; POISSON DISTRIBUTION; RADIATION ONCOLOGY; SPECIALTIES, SURGICAL; UNITED STATES;

EID: 79952322862     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq549     Document Type: Article

References (57)

1. National Cancer Institute. NCI Features: Clinical Trials and You. http:// www.cancer.gov/clinicaltrials. Accessed December 22, 2010.
2. Lara PN, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728-1733. (Pubitemid 32230874)
3. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20(8):2109-2117. (Pubitemid 34408802)
4. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomized controlled trials: a systematic review. J Clin Epidemiol. 1999;52(12):1143-1156. (Pubitemid 29535414)
5. Pinto HA, McCaskill-Stevens W, Wolfe P, Marcus AC. Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) initiative. Ann Epidemiol. 2000; 10(8 suppl):S78-S84.
6. Fallowfeld L, Ratcliffe D, Souhami R. Clinicians' attitudes to clinical trials of cancer therapy. Eur J Cancer. 1997;33(13):2221-2229. (Pubitemid 28123414)
7. Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7(2):141-148. (Pubitemid 43159500)
8. Goldberg KB. Physician attitudes and trial enrollment. Cancer Lett. 2007; 33(22):5-6.
9. Howerton MW, Gibbons MC, Baff CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007;109(3):465-476. (Pubitemid 46190954)
10. McCaskell-Stevens W, Pinto H, Marcus AC, et al. Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. J Clin Oncol. 1999;17(3):1029-1039. (Pubitemid 29109337)
11. Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002;95(5):989-996. (Pubitemid 34925347)
12. Hudson SV, Momperousse D, Leventhal H. Physician perspectives on cancer clinical trials and barriers to minority recruitment. Cancer Control. 2005;12(suppl 2):93-96.
13. Leitch AM, Beitsch PD, McCall LM, et al. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005;190(4):539-542. (Pubitemid 41306071)
14. Nguyen TT, Somkin CP, Ma Y. Participation of Asian-American women in cancer chemoprevention research: physician perspectives. Cancer. 2005;104(12 suppl):3006-3014. (Pubitemid 41798272)
15. Somkin CP, Altschuler A, Ackerson L, et al. Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care. 2005; 11(7):413-421. (Pubitemid 41022725)
16. Meropol NJ, Buzaglo JS, Millard J. Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw. 2007; 5(8):655-664. (Pubitemid 47492764)
17. Schroen AT, Brenin DR. Clinical trial priorities among surgeons caring for breast cancer patients. Am J Surg. 2008;195(4):474-480. (Pubitemid 351417480)
18. Benson AB, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991;9(11):2067-2075.
19. National Cancer Institute. Cancer Care Outcomes Research and Surveillance Consortium. http://healthservices.cancer.gov/cancors/. Accessed December 22, 2010.
20. Ayanian JZ, Chrischilles EA, Fletcher RH, et al. Understanding cancer treatment and outcome: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol. 2004;22(15):2992-2996.
21. Catalano P. Representativeness of CanCORS participants relative to Surveillance, Epidemiology, and End Results (SEER) cancer registries. Paper presented at Academy Health Annual Research meeting; June 8, 2008; Washington, DC.
22. Andersen R, Aday LA. Access to medical care in the U.S.: realized and potential. Med Care. 1978;16(6):533-546. (Pubitemid 8394846)
23. Andersen RM. Revisting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1-10.
24. Phillips KA, Morrison KR, Andersen R, Aday LA. Understanding the context of healthcare utilization: assessing environmental and provider-related variables in the behavioral model of utilization. Health Serv Res. 1998;33(3, pt 1):571-596.
25. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol. 2008;26(15):2532-2537.
26. Little RJ, Rubin DB. Statistical Analysis With Missing Data. New York, NY: Wiley; 2002.
27. He Y, Zaslavsky AM, Harrington DP, Catalano P, Landrum MB. Multiple imputation in a large-scale complex survey: a practical guide. Stat Methods Med Res. 2010 Dec;19(6):653-70. Epub 2009 Aug 4.
28. Korn E, Graubard B. Analysis of Health Surveys. New York, NY: Wiley; 1999.
29. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999;55(2):652-659. (Pubitemid 29302598)
30. Lambert D. Zero-infated Poisson regression, with an application to defects in manufacturing. Technometrics. 1992;34(1):1-14.
31. Siminoff LA. Why learning to communicate with our patients is so important: using communication to enhance accrual to cancer clinical trials. J Clin Oncol. 2008;26(16):2614-2615.
32. Umutyan A, Chiechi C, Beckett LA, et al. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008; 112(1):212-219.
33. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press; 2010.
34. Sung NS, Crowley WF Jr, Genel M, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003;289(10):1305-1306.
35. Avins AL, Goldberg H. Creating a culture of research. Contemp Clin Trials. 2007;28(4):557-562. (Pubitemid 46755035)
36. Kolata G. Forty years' war: lack of study volunteers may hobble cancer fght. New York Times. August 3, 2009.
37. Erickson C, Salsberg E, Forte G, Bruinooge S, Goldstein M. Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract. 2007;3(12):79-86. (Pubitemid 351593695)
38. Warren JL, Mariotto AB, Meekens A, Topor M, Brown ML. Current and future utilization of services from medical oncologists. J Clin Oncol. 2008; 26(19):3242-3247.
39. American Society of Clinical Oncology. Status of the medical oncology workforce. J Clin Oncol. 1996;14(9):2612-2621.
40. Siminoff LA, Zhang A, Colabianchi N, Sturm CM, Shen Q. Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol. 2000;18(6):1203-1211. (Pubitemid 30159837)
41. National Cancer Institute. Cancer Centers Program. http://cancercenters. cancer.gov. Accessed December 22, 2010.
42. National Cancer Institute. Division of Cancer Prevention. Community Clinical Oncology Program (CCOP). http://prevention.cancer.gov/programs- resources/programs/ccop. Accessed December 22, 2010.
43. Academy for Educational Development. Review of best practices for participant recruitment into clinical trials. Report prepared for the National Cancer Institute under contract GS-00F-0007M, order no. 265-FQ-613301, task C1. 2007.
44. Sherwood PR, Given BA, Scholnik A, Given CW. To refer or not to refer: factors that affect primary care provider referral of patients with cancer to clinical treatment trials. J Cancer Educ. 2004;19(1):58-65. (Pubitemid 38543866)
45. McKinney MM, Weiner BJ, Carpenter WR. Building community capacity to participate in cancer prevention research. Cancer Control. 2006; 13(4):295-302. (Pubitemid 44600941)
46. Klabunde CN, Ambs A, Keating NL, et al. The role of primary care physicians in cancer care. J Gen Intern Med. 2009;24(9):1029-1036.
47. Curran WJ, Schiller JH, Wolkin AC, Comis RL. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer. 2008;9(4):222-226.
48. Twelves CJ, Thomson CS, Young J, Gould A. Entry into clinical trials in breast cancer: the importance of specialist teams. Eur J Cancer. 1998;34(7): 1004-1007. (Pubitemid 28308339)
49. National Cancer Institute. Report of the Clinical Trials Working Group of the National Cancer Advisory Board: restructuring the national cancer clinical trials enterprise. 2005. http://restructuringtrials.cancer.gov/fle/ctwg-reports. pdf.
50. Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996;88(12):812-816. (Pubitemid 26187390)
51. Rogers SO Jr, Gray SW, Landrum MB, et al. Variations in surgeon treatment recommendations for lobectomy in early-stage non-small-cell lung cancer by patient age and comorbidity. Ann Surg Oncol. 2010;17(6):1581-1588.
52. Hillman AL, Pauly MV, Kerstein JJ. How do fnancial incentives affect physicians' clinical decisions and the fnancial performance of health maintenance organizations? N Engl J Med. 1989;321(2):86-92. (Pubitemid 19170397)
53. Petersen LA, Woodard LD, Urech T, Daw C, Sookanan S. Does pay-for-performance improve the quality of health care? Ann Intern Med. 2006; 145(4):265-272. (Pubitemid 46768610)
54. Taylor KM, Feldstein ML, Skeel RT, Pandya KJ, Ng P, Carbone P. Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol. 1994;12(9):1796-1805.
55. Voelker R. Experts say projected surgeon shortage a "looming crisis" for patient care. JAMA. 2009;302(14):1520-1521.
56. Bodenheimer T. Primary care: will it survive? N Engl J Med. 2006;355(9): 861-864.
57. Clauser SB, Johnson MR, O'Brien DM, Beveridge JM, Fennell ML, Kaluzny AD. Improving clinical research and cancer care delivery in community settings: evaluating the NCI community cancer centers program. Implement Sci. 2009;4:63.